Introducing SOHO Insider
SOHO Insider EIC Sagar Lonial, MD, announces the new digital and print newsroom SOHO Insider from the Society of Hematologic Oncology (SOHO).
Multiple Myeloma
News
66th American Society of Hematology Annual Meeting & Exposition
Leukemia
Fixed-duration regimens outperform SOC in treatment-naïve CLL
Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab improved progression-free survival over fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab in treatment-naïve chronic lymphocytic leukemia (TN CLL), according
66th American Society of Hematology Annual Meeting & Exposition
Leukemia
Asciminib benefit-risk profile bests other TKIs in CML
Results from the phase 3 ASC4FIRST study presented at the 2024 American Society of Hematology Annual Meeting & Exposition showed that asciminib had
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Lymphoma
Tafasitamab plus lenalidomide, rituximab improves PFS in patients with relapsed or refractory follicular lymphoma
Addition of tafasitamab, a humanized CD19-targeting monoclonal antibody (mAb), to lenalidomide plus rituximab resulted in significant and clinically meaningful improvement in progression-free survival (PFS),
Meetings / Conferences
MDS
Smoking associated with MDS mutations, progression
Results from a prospective study presented at the American Society of Hematology Annual Meeting & Exposition showed that tobacco smoking was associated with
Society Updates
Save the date for SOHO 2025 in Houston, Texas
The Society of Hematologic Oncology (SOHO) has announced that its 2025 meeting will be held between Wednesday, September 3, 2025, and Saturday, September
Cellular Therapy
T-Cell Lymphoma
CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma
The chimeric antigen receptor (CAR)-T cell therapy CTX130 (volamcabtagene durzigedleucel) showed encouraging results in patients with heavily pretreated relapsed or refractory T-cell lymphoma,
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Novel immune checkpoint blocker ‘well-tolerated’ in DLBCL
FS118, a new potential immune checkpoint blocker, was well tolerated in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) with
Multiple Myeloma
MRD2STOP trial supports discontinuation of maintenance therapy in MM patients with low MRD negativity
Maintenance therapy discontinuation in patients with deep measurable residual disease (MRD) negativity (<10⁻⁶ or <10⁻⁷) is associated with low rates of disease resurgence
Society Updates
Why join the Society of Hematologic Oncology (SOHO)?
Rami Komrokji, MD, of the Moffitt Cancer Center in Tampa, Florida, and 2024-2025 SOHO President Phillip Scheinberg, MD, PhD, of the Hospital Sao